DK2197428T3 - Forbedret farmaceutisk sammensætning, der indeholder et pyrrolidon-antikrampemiddel, og fremgangsmåde til fremstilling heraf - Google Patents

Forbedret farmaceutisk sammensætning, der indeholder et pyrrolidon-antikrampemiddel, og fremgangsmåde til fremstilling heraf

Info

Publication number
DK2197428T3
DK2197428T3 DK07819022.0T DK07819022T DK2197428T3 DK 2197428 T3 DK2197428 T3 DK 2197428T3 DK 07819022 T DK07819022 T DK 07819022T DK 2197428 T3 DK2197428 T3 DK 2197428T3
Authority
DK
Denmark
Prior art keywords
preparation
pharmaceutical composition
composition containing
improved pharmaceutical
pyrrolidone
Prior art date
Application number
DK07819022.0T
Other languages
English (en)
Inventor
Dimitrios Bikiaris
Evangelos Karavas
Efthimios Koutris
Vicky Samara
Ioanna Koutri
Eleni Stathaki
Original Assignee
Pharmathen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen Sa filed Critical Pharmathen Sa
Application granted granted Critical
Publication of DK2197428T3 publication Critical patent/DK2197428T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DK07819022.0T 2007-10-16 2007-10-16 Forbedret farmaceutisk sammensætning, der indeholder et pyrrolidon-antikrampemiddel, og fremgangsmåde til fremstilling heraf DK2197428T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2007/008952 WO2009049642A1 (en) 2007-10-16 2007-10-16 Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof

Publications (1)

Publication Number Publication Date
DK2197428T3 true DK2197428T3 (da) 2012-04-02

Family

ID=39494325

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07819022.0T DK2197428T3 (da) 2007-10-16 2007-10-16 Forbedret farmaceutisk sammensætning, der indeholder et pyrrolidon-antikrampemiddel, og fremgangsmåde til fremstilling heraf

Country Status (10)

Country Link
US (1) US8187635B2 (da)
EP (1) EP2197428B1 (da)
AT (1) ATE542525T1 (da)
CA (1) CA2696977C (da)
CY (1) CY1112702T1 (da)
DK (1) DK2197428T3 (da)
ES (1) ES2380010T3 (da)
PL (1) PL2197428T3 (da)
WO (1) WO2009049642A1 (da)
ZA (1) ZA201003380B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010306830C1 (en) 2009-10-13 2015-05-28 Allomek Therapeutics Llc Novel mek inhibitors, useful in the treatment of diseases
US9333175B2 (en) * 2010-06-16 2016-05-10 Mylan Inc. Controlled release levetiracetam formulations and methods for producing the same
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
WO2014144512A1 (en) 2013-03-15 2014-09-18 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
JP6422464B2 (ja) * 2016-05-19 2018-11-14 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
CA3149491A1 (en) * 2019-08-06 2021-02-11 Justin KIRKLAND Formulations including dihydrohonokiol
CN114917195A (zh) * 2022-06-13 2022-08-19 河北戴桥医药科技有限公司 一种吡拉西坦片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
US7132552B2 (en) * 2003-02-03 2006-11-07 Teva Pharmaceutical Industries, Ltd. Process for producing levetiracetam
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
JP2008534522A (ja) * 2005-03-30 2008-08-28 ジェンファーム インク 医薬組成物のための複合ステップ製造方法
NL2000281C2 (nl) * 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
PT1810676E (pt) * 2006-01-24 2009-01-02 Teva Pharma Formulações de levetiracetam e métodos para a sua preparação

Also Published As

Publication number Publication date
PL2197428T3 (pl) 2012-06-29
ATE542525T1 (de) 2012-02-15
CY1112702T1 (el) 2016-02-10
EP2197428A1 (en) 2010-06-23
US20110033538A1 (en) 2011-02-10
ZA201003380B (en) 2011-12-28
US8187635B2 (en) 2012-05-29
WO2009049642A1 (en) 2009-04-23
ES2380010T3 (es) 2012-05-07
EP2197428B1 (en) 2012-01-25
CA2696977C (en) 2012-12-04
CA2696977A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
DK2197428T3 (da) Forbedret farmaceutisk sammensætning, der indeholder et pyrrolidon-antikrampemiddel, og fremgangsmåde til fremstilling heraf
WO2008141731A3 (en) Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
BRPI0616694B8 (pt) processo para preparar comprimido farmacêutico com 80 e 96% em peso com base no peso seco de vildagliptina e metformina ou seus sais farmaceuticamente aceitáveis
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
TW200745003A (en) Novel compounds
UA99136C2 (ru) Улучшенная фармацевтическая композиция, содержащая антагонист кальциевых каналов - лерканидипин, способ ее получения
TNSN07435A1 (en) Novel piperidine carboxylic acid amide derivatives
PL1981877T3 (pl) Związki N-hydroksyakryloamidowe
PH12017501397B1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
TW200800940A (en) New primary amines
WO2009049648A3 (en) Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof
SA518392325B1 (ar) حمض (2s،4r)-5-(5'-كلورو -2'-فلورو-[1،1'-باي فينيل ]-4-يل )-2-(إيثوكسي ميثيل )-4-(3-هيدروكسي أيزوكسازول -5-كربوكساميدو )-2-ميثيل بنتانويك بلوري واستخداماته
PE20211391A1 (es) Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-acido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmaceutico
ECSP088464A (es) Compuesto para la inhibición de la apoptosis
MX2012002209A (es) Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos.
WO2007098945A3 (en) Stable solid dosage form comprising desmopressin
EA200970708A1 (ru) Фармацевтические композиции, включающие аторвастатин и никотиновую кислоту
GB0620619D0 (en) Novel compounds
DK1906931T3 (da) Forberedt farmaceutisk præparat, de indeholder ACE-inhibitor og fremgangsmåde til fremstilling deraf
EA200901205A1 (ru) Фармацевтическая композиция, содержащая соль розиглитазона
WO2007052167A3 (en) Stable composition for a pharmaceutical formulation containing olanzapine
UA95909C2 (en) Piperidine carboxylic acid amide derivatives
WO2010067989A2 (ko) 신규한 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물